Mona Kamal El-Awam
Asst. Professor
The Impact of NF-κB and Keap1/Caspase-3 Signaling Pathway on protective Effects of sitagliptin in a Rat Model of Doxorubicin-Induced Cardiac Dysfunction
• 2025
Publication Information
Authors
Mahmoud M. Hassan1*, Enas M. Kasem1, Walaa H. Mohammed1, Manar A. Elkholy2,
Alzahraa Z. Elsayed2, Eman Mohamed Faruk 3,4, Mona K. Alawam1
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Background: Doxorubicin (DOX) treatment is a primary cause of chemotherapy-induced
cardiotoxicity. Antidiabetic sitagliptin (STG) has been shown to improve cardiovascular
functions through anti-inflammatory, antioxidant, and anti-apoptotic effects. Oxidative stress
plays a crucial role in the development of various cardiovascular diseases, especially those
related to endothelial dysfunction. The transcription factor nuclear factor erythroid-2-like 2
(Nrf2) is the main regulator of antioxidant defense mechanisms. Nrf2, along with its
suppressor protein Kelch-like ECH-associated protein 1 (Keap1), controls the levels of
reactive oxygen species (ROS). Objective: This study aimed to evaluate the role of the
Nrf2/caspase-3 signaling pathway in the cardiotoxic effect of DOX and the potential role of
sitagliptin (STG). Materials and Methods:Rats were divided into four groups, each
comprising eight animals (n=8): a control group, an STG group (receiving 10 mg/kg/day for
21 days), a DOX group (receiving 1mg/kg i.p per day for five injections week for 3 weeks)
and STG+DOX group (treated by STG and DOX as previously mentioned). Results: The
effect of DOX on cardiac tissue detected a significant reductionin ABP and deviated ST
segment, while STG improved DOX-induced cardiotoxicity markers, oxidative stress, and
inflammatory markers. Also, STG regulates cardiovascular hemodynamics and reduces both
cardiac caspase-3 and Keap-1 and upregulates NrF2 gene expression levels. Conclusion:
STG administration can exert protective effects against doxorubicin-induced cardiac toxicity
through anti-inflammatory, antioxidant, and anti-apoptotic properties, in addition to
promoting the Nrf2 signaling pathway.
cardiotoxicity. Antidiabetic sitagliptin (STG) has been shown to improve cardiovascular
functions through anti-inflammatory, antioxidant, and anti-apoptotic effects. Oxidative stress
plays a crucial role in the development of various cardiovascular diseases, especially those
related to endothelial dysfunction. The transcription factor nuclear factor erythroid-2-like 2
(Nrf2) is the main regulator of antioxidant defense mechanisms. Nrf2, along with its
suppressor protein Kelch-like ECH-associated protein 1 (Keap1), controls the levels of
reactive oxygen species (ROS). Objective: This study aimed to evaluate the role of the
Nrf2/caspase-3 signaling pathway in the cardiotoxic effect of DOX and the potential role of
sitagliptin (STG). Materials and Methods:Rats were divided into four groups, each
comprising eight animals (n=8): a control group, an STG group (receiving 10 mg/kg/day for
21 days), a DOX group (receiving 1mg/kg i.p per day for five injections week for 3 weeks)
and STG+DOX group (treated by STG and DOX as previously mentioned). Results: The
effect of DOX on cardiac tissue detected a significant reductionin ABP and deviated ST
segment, while STG improved DOX-induced cardiotoxicity markers, oxidative stress, and
inflammatory markers. Also, STG regulates cardiovascular hemodynamics and reduces both
cardiac caspase-3 and Keap-1 and upregulates NrF2 gene expression levels. Conclusion:
STG administration can exert protective effects against doxorubicin-induced cardiac toxicity
through anti-inflammatory, antioxidant, and anti-apoptotic properties, in addition to
promoting the Nrf2 signaling pathway.